<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805960</url>
  </required_header>
  <id_info>
    <org_study_id>CONVERT-AF Version5 22.01.2013</org_study_id>
    <nct_id>NCT01805960</nct_id>
  </id_info>
  <brief_title>Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF</brief_title>
  <acronym>CONVERT-AF</acronym>
  <official_title>Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy of a single injection of Canakinumab on AF&#xD;
      recurrences within 6 months after electrical cardioversion in patients with persistent AF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of atrial fibrillation</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial fibrillation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma levels of C-reactive protein</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first redo cardioversion</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 s.c. injection of canakinumab 150mg directly after cardioversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 s.c. injection directly after cardioversion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <arm_group_label>Canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  EKG-documented AF&#xD;
&#xD;
          -  Undergoing electrical cardioversion&#xD;
&#xD;
          -  C-reactive protein ≥1.25mg/L&#xD;
&#xD;
          -  Age ≥ 50 years, women need to be postmenopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undergoing urgent cardioversion because of medical instability&#xD;
&#xD;
          -  AF persistence after cardioversion or AF recurrence before randomization&#xD;
&#xD;
          -  Atrial flutter&#xD;
&#xD;
          -  Severe renal failure (creatinine clearance &lt;30 ml/min)&#xD;
&#xD;
          -  Known active or recurrent hepatic disorder (including cirrhosis, hepatitis A, B or C,&#xD;
             or Alanine transaminase/aspartate aminotransferase levels &gt;3x ULN or total bilirubin&#xD;
             &gt;2x ULN)&#xD;
&#xD;
          -  History of malignancy other than basal cell skin carcinoma&#xD;
&#xD;
          -  Known intolerance or allergic reactions to canakinumab&#xD;
&#xD;
          -  Use of amiodarone within the last 6 months&#xD;
&#xD;
          -  Known HIV or any other immune compromised state including neutropenia or&#xD;
             immunodeficiency&#xD;
&#xD;
          -  History of ongoing, chronic or recurrent infectious disease&#xD;
&#xD;
          -  History or evidence of active tuberculosis (TB) infection at Visit 1 or one of the&#xD;
             risk factors for tuberculosis such as but not limited or exclusive to:&#xD;
&#xD;
               -  History of any of the following: residence in a congregate setting (e.g. jail or&#xD;
                  prison, homeless shelter, or chronic care facility), substance abuse (e.g.&#xD;
                  injection or noninjection), health-care workers with unprotected exposure to&#xD;
                  patients who are at high risk of TB or patients with TB disease before the&#xD;
                  identification and correct airborne precautions of the patient.&#xD;
&#xD;
               -  Close contact (i.e. share the same air space in a household or other enclosed&#xD;
                  environment for a prolonged period (days or weeks, not minutes or hours)) with a&#xD;
                  person with active pulmonary TB disease within the last 12 months.&#xD;
&#xD;
               -  Evidence of tuberculosis infection, at Visit 1, determined as defined by local&#xD;
                  guidelines/ local medical practice (see also below for determination of&#xD;
                  tuberculosis status). If presence of tuberculosis is established then treatment&#xD;
                  (according to local guidelines) must have been completed prior to randomization.&#xD;
                  Completion of treatment is determined by local TB guidelines or in the absence of&#xD;
                  such guidelines the following has to be demonstrated: TB has been treated&#xD;
                  adequately with antibiotics, cure can be demonstrated, and risk factors resulting&#xD;
                  in TB exposure and contracting TB have been removed (e.g. the patient does not&#xD;
                  live anymore in high TB exposure setting).&#xD;
&#xD;
          -  Patients on systemic corticosteroids or other anti-inflammatory drugs other than&#xD;
             non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Patients on any biological drug targeting the immune system&#xD;
&#xD;
          -  Acute coronary syndrome or acute stroke within 3 months&#xD;
&#xD;
          -  History of heart failure hospitalization within 3 months&#xD;
&#xD;
          -  Planned major surgery including planned coronary artery bypass grafting&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Live vaccinations within 3 months prior to the randomization visit (visit 2) or live&#xD;
             vaccinations planned during the trial.&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Inability to comply with the study protocol&#xD;
&#xD;
          -  Previously enrolled in CONVERT-AF&#xD;
&#xD;
          -  Patients who have received an investigational drug or device within 30 days of first&#xD;
             visit.&#xD;
&#xD;
          -  History of alcohol and/or substance abuse that could interfere with the conduct of the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Conen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG Geneve</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

